Technical Analysis for EPZM - Epizyme, Inc.

Grade Last Price % Change Price Change
grade C 12.08 -1.55% -0.19
EPZM closed down 1.55 percent on Tuesday, March 19, 2019, on 1.23 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical EPZM trend table...

Date Alert Name Type % Chg
Mar 19 20 DMA Resistance Bearish 0.00%
Mar 19 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Mar 19 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 18 20 DMA Resistance Bearish -1.55%
Mar 18 1,2,3 Pullback Bullish Bullish Swing Setup -1.55%
Mar 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.55%
Mar 18 Inside Day Range Contraction -1.55%
Mar 15 Fell Below 20 DMA Bearish -1.23%
Mar 15 Outside Day Range Expansion -1.23%
Mar 13 Spinning Top Other -6.07%

Older signals for EPZM ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Epizyme, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, planning, and commercialization of various personalized therapeutics for the treatment of patients with genetically defined cancers. Its principal product candidates under development include EPZ-5676, an intravenously administered small molecule inhibitor of DOT1L that is in Phase I clinical trials for the treatment of mixed lineage rearranged leukemia (MLL-r); and EPZ-6438, an orally available small molecule inhibitor of EZH2 for the treatment of non-Hodgkin lymphoma patients caused by an oncogenic point mutation in EZH2. The company has strategic collaboration and license agreements with Celgene Corporation and Celgene International Sàrl, as well as Glaxo Group Limited to discover, develop, and commercialize small molecule HMT inhibitors; and Eisai Co., Ltd. (Eisai) to license its EZH2 program. It also has a companion diagnostic collaboration with Abbott Molecular Inc. for the development of a companion diagnostic to identify patients with the MLL-r genetic alteration targeted by EPZ-5676; and with Roche Molecular Systems, Inc., as well as with Eisai for the development and commercialization of a companion diagnostic for use with EPZ-6438 product candidate. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Biotechnology Life Sciences Cancers Leukemia Celgene Non Hodgkin Lymphoma Eisai Ezh2 Treatment Of Non Hodgkin Lymphoma
Is EPZM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 19.55
52 Week Low 5.14
Average Volume 902,625
200-Day Moving Average 10.5467
50-Day Moving Average 11.3162
20-Day Moving Average 12.4935
10-Day Moving Average 12.326
Average True Range 0.7367
ADX 33.99
+DI 21.7508
-DI 18.09
Chandelier Exit (Long, 3 ATRs ) 12.7399
Chandelier Exit (Short, 3 ATRs ) 13.6701
Upper Bollinger Band 13.6497
Lower Bollinger Band 11.3373
Percent B (%b) 0.32
BandWidth 18.508825
MACD Line 0.2827
MACD Signal Line 0.4437
MACD Histogram -0.161
Fundamentals Value
Market Cap 706.27 Million
Num Shares 58.5 Million
EPS -2.07
Price-to-Earnings (P/E) Ratio -5.84
Price-to-Sales 55.00
Price-to-Book 6.25
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.15
Resistance 3 (R3) 13.20 12.89 12.97
Resistance 2 (R2) 12.89 12.62 12.87 12.91
Resistance 1 (R1) 12.49 12.45 12.34 12.44 12.85
Pivot Point 12.18 12.18 12.11 12.16 12.18
Support 1 (S1) 11.78 11.91 11.63 11.73 11.31
Support 2 (S2) 11.47 11.74 11.45 11.25
Support 3 (S3) 11.07 11.47 11.19
Support 4 (S4) 11.02